Do hematologists recommend using tocilizumab with bispecific antibodies for relapsed Multiple Myeloma?
Bispecific antibodies (BsAbs) are a powerful treatment for relapsed/refractory multiple myeloma, but they often cause cytokine release syndrome (CRS), a side effect where the immune system overreacts. Tocilizumab is a drug that blocks the IL-6 receptor and is used to control CRS. A 2025 review of expert opinions from hematologists confirms that tocilizumab is recommended for managing CRS in this setting, including using it preventively in outpatient care.
What the research says
A 2025 qualitative review based on interviews with ten hematologists/oncologists (four from academic centers, six from community practices) found that bispecific antibodies are consistently regarded as highly effective for relapsed/refractory multiple myeloma, especially in heavily pretreated patients 6. The most common acute toxicity is cytokine release syndrome (CRS), which is generally low-grade and managed effectively with early use of tocilizumab 6. Experts also described prophylactic use of tocilizumab in outpatient settings to prevent or reduce CRS severity 6. The review emphasizes that coordinated care teams and evolving infrastructure are needed to support BsAb therapy, but tocilizumab remains a key part of the management strategy 6. No other sources in the provided set directly address tocilizumab or bispecific antibodies; the other sources cover different treatments (e.g., selinexor, lenalidomide, pomalidomide, lisaftoclax) or unrelated topics (proteasome inhibitors, gamma delta T cells, proteomics) 1234578.
What to ask your doctor
- If I am prescribed a bispecific antibody, what is the plan for monitoring and managing cytokine release syndrome (CRS)?
- Would tocilizumab be used if I develop CRS, and would it be given in the clinic or at home?
- Is prophylactic (preventive) tocilizumab an option for me to reduce the risk of CRS?
- What other side effects of bispecific antibodies should I watch for, and how are they managed?
- How does the care team coordinate between outpatient and inpatient settings for this treatment?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.